Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes
- 1 September 1999
- journal article
- clinical trial
- Published by Elsevier in Metabolism
- Vol. 48 (9) , 1102-1107
- https://doi.org/10.1016/s0026-0495(99)90122-1
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fatDiabetes, 1997
- Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular diseaseDiabetes, 1997
- Health Consequences of Fat DistributionHormone Research, 1997
- Effects of a New Oral Hypoglycaemic Agent (CS-045) on Metabolic Abnormalities and Insulin Resistance in Type 2 DiabetesDiabetic Medicine, 1994
- Metabolic Effects of New Oral Hypoglycemic Agent CS-045 in NIDDM SubjectsDiabetes Care, 1992
- A pilot clinical trial of a new oral hypoglycemic agent, CS-045, in patients with non-insulin dependent diabetes mellitusDiabetes Research and Clinical Practice, 1991
- Pathogenesis of insulin resistance and hyperglycemia in non-insulin-dependent diabetes mellitusThe American Journal of Medicine, 1985
- An ascochlorin derivative, AS-6, reduces insulin resistance in the genetically obese diabetic mouse, db/dbDiabetes, 1985
- Ciglitazone, a new hypoglycemic agent. I. Studies in ob/ob and db/db mice, diabetic Chinese hamsters, and normal and streptozotocin-diabetic ratsDiabetes, 1983
- Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agentDiabetes, 1983